SAP sued by o9 Solutions over alleged trade secret theft
Investing.com - Stifel has reiterated its Buy rating and $5.00 price target on Pulmonx Corp. (NASDAQ:LUNG) following the company’s third-quarter 2025 earnings report. This target represents a 173% upside from the current price of $1.83, aligning with the broader analyst consensus of "Buy" and InvestingPro data suggesting the stock is currently undervalued.
Pulmonx reported third-quarter sales of $21.5 million, representing approximately 5% year-over-year growth on a reported basis and about 4% growth excluding foreign exchange effects, matching the company’s late-October preannouncement. While this quarterly growth is modest, InvestingPro data shows the company has achieved 15.6% revenue growth over the last twelve months, reaching $91.7 million.
The medical device company recently welcomed back its previous management team, with Glen French returning as CEO and Derrick Sung as CFO, marking a leadership transition that coincides with revised guidance.
Pulmonx has lowered its full-year 2025 sales guidance to a range of $89 million to $90 million, implying 6-7% year-over-year growth, down from the previous forecast of $90 million to $92 million, citing a desire to establish targets the company has "a high degree of confidence in achieving."
During the post-earnings conference call, the returning executives outlined plans to accelerate profitable growth, drive more meaningful operating leverage, and extend the company’s cash runway.
In other recent news, Pulmonx Corp reported its financial results for the third quarter of 2025, exceeding analysts’ expectations. The company achieved an earnings per share (EPS) of -$0.34, surpassing the anticipated -$0.4198. Pulmonx also reported revenue of $21.5 million, which was higher than the forecasted $20.78 million. These results indicate a positive earnings surprise for the company. Despite the favorable financial performance, some investor concerns about future growth prospects were noted. Additionally, analyst firms have not made any recent changes to their ratings for Pulmonx. The company’s recent developments reflect a focus on financial performance, with an emphasis on surpassing revenue and earnings expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.